Log in Register
Menu

MCF7/182R-7 Cell Line

Invented by Dr Anne Lykkesfeldt at Danish Cancer Society

Info

Catalogue Number 152106
Antigen/Gene or Protein Targets Oestrogen receptor
Parental Line MCF7 S0.5
Host Human
Tissue Breast
Disease Keywords Breast cancer, fulvestrant resistant
Model Tumour line
Relevance The MCF7/182R-7 Cell line is a breast cancer cell line resistant to fulvestrant. Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.
Production Details The MCF7/182R-7 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, Lykkesfeldt et al (1995). The MCF7/182R-7 cells can be maintained continuously in growth medium with 100 nM fulvestrant.
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2.5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance.
Notes Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level. The MCF7/182R-7 cells do not express progesterone receptor. The MCF7/182R-7 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells.

Passage 427(AL3419), 430 (AL3779)
Cellosaurus ID CVCL_1D41

References: 7 entries

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-75. PMID: 18409071.

Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041.

Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194.

Christensen et al. 2004. Breast Cancer Res Treat. 85(1):53-63. PMID: 15039597.

Larsen et al. 1997. Int J Cancer. 72(6):1129-36. PMID: 9378550.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.


Add a reference

References: 7 entries

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-75. PMID: 18409071.

Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041.

Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194.

Christensen et al. 2004. Breast Cancer Res Treat. 85(1):53-63. PMID: 15039597.

Larsen et al. 1997. Int J Cancer. 72(6):1129-36. PMID: 9378550.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.


Add a reference

References: 7 entries

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-75. PMID: 18409071.

Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041.

Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194.

Christensen et al. 2004. Breast Cancer Res Treat. 85(1):53-63. PMID: 15039597.

Larsen et al. 1997. Int J Cancer. 72(6):1129-36. PMID: 9378550.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.


Add a reference


This reagent does not have any reviews at the moment.